M. Duffy, O. Grady, P. Devaney, D. O-'siorain, L. Fennelly et al., Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report, Cancer, vol.42, issue.3, pp.531-533, 1988.
DOI : 10.1002/1097-0142(19880801)62:3<531::AID-CNCR2820620315>3.0.CO;2-B

F. Janicke, M. Schmitt, and H. Graeff, Clinical Relevance of the Urokinase-Type and Tissue-Type Plasminogen Activators and of Their Type 1 Inhibitor in Breast Cancer, Seminars in Thrombosis and Hemostasis, vol.17, issue.03, pp.303-312, 1991.
DOI : 10.1055/s-2007-1002624

F. Janicke, M. Schmitt, L. Pache, K. Ulm, N. Harbeck et al., Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer, Breast Cancer Research and Treatment, vol.235, issue.3, pp.195-208, 1993.
DOI : 10.1007/BF01833260

N. Harbeck, C. Thomssen, U. Berger, K. Ulm, R. Kates et al., Invasion marker PAI???1 remains a strong prognostic factor after long???term follow???up both for primary breast cancer and following first relapse, Breast Cancer Research and Treatment, vol.83, issue.2, pp.147-157, 1999.
DOI : 10.1023/A:1006118828278

J. Foekens, H. Peters, M. Look, H. Portengen, M. Schmitt et al., The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients, Cancer Res, vol.60, pp.636-643, 2000.

S. Hansen, J. Overgaard, C. Rose, A. Knoop, A. Laenkholm et al., Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patients, British Journal of Cancer, vol.88, issue.1, pp.102-108, 2003.
DOI : 10.1038/sj.bjc.6600662

M. Look, W. Van-putten, M. Duffy, N. Harbeck, I. Christensen et al., Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients, JNCI Journal of the National Cancer Institute, vol.94, issue.2, pp.116-128, 2002.
DOI : 10.1093/jnci/94.2.116

F. Janicke, A. Prechtl, C. Thomssen, N. Harbeck, C. Meissner et al., Randomized Adjuvant Chemotherapy Trial in High-Risk, Lymph Node-Negative Breast Cancer Patients Identified by Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1, JNCI Journal of the National Cancer Institute, vol.93, issue.12, pp.913-920, 2001.
DOI : 10.1093/jnci/93.12.913

N. Harbeck, R. Kates, and M. Schmitt, Clinical Relevance of Invasion Factors Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1 for Individualized Therapy Decisions in Primary Breast Cancer Is Greatest When Used in Combination, Journal of Clinical Oncology, vol.20, issue.4, pp.1000-1007, 2002.
DOI : 10.1200/JCO.2002.20.4.1000

N. Harbeck, R. Kates, M. Look, M. Meijer-van-gelder, J. Klijn et al., Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424), Cancer Res, vol.62, pp.4617-4622, 2002.

P. Manders, V. Tjan-heijnen, P. Span, N. Grebenchtchikov, J. Foekens et al., Predictive Impact of Urokinase-Type Plasminogen Activator: Plasminogen Activator Inhibitor Type-1 Complex on the Efficacy of Adjuvant Systemic Therapy in Primary Breast Cancer, Cancer Research, vol.64, issue.2, pp.659-664, 2004.
DOI : 10.1158/0008-5472.CAN-03-1820

F. Janicke, C. Thomssen, L. Pache, M. Schmitt, H. Graeff et al., Urokinase (uPA) and PAI-1 as selection criteria for adjuvant chemotherapy in axillary node-negative breast cancer patients, Prospects in diagnosis and treatment, pp.207-218

T. Cufer, S. Borstnar, and I. Vrhovec, Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in operable breast cancer, The International Journal of Biological Markers, vol.18, issue.2, pp.106-115, 2003.
DOI : 10.5301/JBM.2008.666

J. Foekens, M. Look, H. Peters, W. Van-putten, H. Portengen et al., Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1: Predictors of Poor Response to Tamoxifen Therapy in Recurrent Breast Cancer, JNCI Journal of the National Cancer Institute, vol.87, issue.10, pp.751-756, 1995.
DOI : 10.1093/jnci/87.10.751

T. Benraad, J. Geurts-moespot, J. Grondahl-hansen, M. Schmitt, J. Heuvel et al., Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): Report of an EORTC/BIOMED-1 Workshop, European Journal of Cancer, vol.32, issue.8, pp.1371-1381, 1996.
DOI : 10.1016/0959-8049(96)00118-9

E. Kaplan and P. Meier, Nonparametric Estimation from Incomplete Observations, Journal of the American Statistical Association, vol.37, issue.282, pp.457-481, 1958.
DOI : 10.1214/aoms/1177731566

R. Peto and M. Pike, Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples, British Journal of Cancer, vol.35, issue.1, pp.1-39, 1977.
DOI : 10.1038/bjc.1977.1

D. Cox, Regression Models and Life-Tables, J R Stat Soc, vol.34, pp.187-220, 1972.
DOI : 10.1007/978-1-4612-4380-9_37

T. Verjat, E. Cerrato, M. Jacobs, P. Leissner, and B. Mougin, Multiparametric duplex real-time nucleic acid sequence-based amplification assay for mRNA profiling, Biotechniques, vol.37, pp.476-481, 2004.

N. Harbeck, R. Kates, M. Schmitt, K. Gauger, M. Kiechle et al., Urokinase-Type Plasminogen Activator and Its Inhibitor Type 1 Predict Disease Outcome and Therapy Response in Primary Breast Cancer, Clinical Breast Cancer, vol.5, issue.5, pp.348-352, 2004.
DOI : 10.3816/CBC.2004.n.040

N. Harbeck, R. Kates, K. Gauger, A. Willems, M. Kiechle et al., Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer, Thrombosis and Haemostasis, vol.91, pp.450-456, 2004.
DOI : 10.1160/TH03-12-0798

C. Sweep, J. Geurts-moespot, N. Grebenschikov, J. De-witte, J. Heuvel et al., External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts, British Journal of Cancer, vol.78, issue.11, pp.1434-1441, 1998.
DOI : 10.1038/bjc.1998.704

B. Han, M. Nakamura, I. Mori, Y. Nakamura, and K. Kakudo, Urokinasetype plasminogen activator system and breast cancer (Review), Oncology Reports, vol.14, pp.105-112, 2005.

C. Escot, Y. Zhao, C. Puech, and H. Rochefort, Cellular localisation byin situ hybridisation of cathepsin D, stromelysin 3, and urokinase plasminogen activator RNAs in breast cancer, Breast Cancer Research and Treatment, vol.45, issue.2, pp.217-226, 1996.
DOI : 10.1007/BF01806676

N. Ishikawa, Y. Endo, and T. Sasaki, Inverse Correlation between mRNA Expression of Plasminogen Activator Inhibitor-2 and Lymph Node Metastasis in Human Breast Cancer, Japanese Journal of Cancer Research, vol.311, issue.Suppl., pp.480-487, 1996.
DOI : 10.1111/j.1349-7006.1996.tb00249.x

T. Umeda, Y. Eguchi, K. Okino, M. Kodama, and T. Hattori, Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues, The Journal of Pathology, vol.53, issue.4, pp.388-397, 1997.
DOI : 10.1002/(SICI)1096-9896(199712)183:4<388::AID-PATH943>3.0.CO;2-I

D. Tong, C. Schneeberger, K. Czerwenka, R. Schmutzler, P. Speiser et al., Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer, Clin Cancer Res, vol.5, pp.1497-1502, 1999.

J. Fisher, C. Field, H. Zhou, T. Harris, M. Henderson et al., Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases -a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases, Breast Cancer Research and Treatment, vol.61, issue.1, pp.1-12, 2000.
DOI : 10.1023/A:1006445129195

A. Ree, M. Pacheco, M. Tvermyr, O. Fodstad, and M. Brentani, Expression of a novel factor, com1, in early tumor progression of breast cancer, Clin Cancer Res, vol.6, pp.1778-1783, 2000.

R. Castello, A. Estelles, C. Vaquez, C. Falco, F. Espana et al., Quantitative real-time reverse transcription- PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer, Clin Chem, vol.48, pp.1288-1295, 2002.

M. Pacheco, I. Nishimoto, M. Neto, M. Mantovani, E. Brentani et al., Prognostic significance of the combined expression of matrix metalloproteinase-9, urokinase type plasminogen activator and its receptor in breast cancer as measured by Northern blot analysis, Int J Biol Markers, vol.16, pp.62-68, 2001.

F. Spyratos, C. Bouchet, S. Tozlu, M. Labroquere, S. Vignaud et al., Prognostic value of uPA, PAI-1 and PAI-2 mRNA expression in primary breast cancer, Anticancer Res, vol.22, pp.2997-3003, 2002.

J. Grohndahl-hansen, I. Christensen, P. Briand, H. Pappot, H. Mouridsen et al., Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients, Clin Cancer Res, vol.3, pp.233-239, 1997.

T. Sakakibara, K. Hibi, Y. Kodera, K. Ito, S. Akiyama et al., Plasminogen Activator Inhibitor-1 as a Potential Marker for the Malignancy of Esophageal Squamous Cell Carcinoma, Clinical Cancer Research, vol.10, issue.4, pp.1375-1378, 2004.
DOI : 10.1158/1078-0432.CCR-03-0196

T. Sakakibara, K. Hibi, M. Koike, M. Fujiwara, Y. Kodera et al., Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer, British Journal of Cancer, vol.8, issue.7, pp.799-803, 2005.
DOI : 10.1186/1471-244X-3-5

T. Brooks, S. Wang, N. Brunner, and P. Charlton, XR a novel modulator of plasminogen activator inhibitor-1 activity, suppresses tumor cell invasion and angiogenesis in vitro, Anticancer Drugs, vol.5967, issue.1, pp.37-44